Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sajeve S. Thomas"'
Autor:
Bin Zhang, F. Stephen Hodi, Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Stephen Francis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 4, Iss 1 (2016)
Background Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant admi
Externí odkaz:
https://doaj.org/article/0f77214448854233aa98f583d805a4de
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Serum concentration of intact sacituzumab govitecan and hRS7 IgG taken 30 min after injection for each of the 4 dose levels tested.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2455a3d85f2cadfc9c90464a485cb5fc
https://doi.org/10.1158/1078-0432.22457147
https://doi.org/10.1158/1078-0432.22457147
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
This file contains additional methods, including eligibility criteria, study design, pharmacokinetics and immunogenicity, and immunohistology, as well as additional results related to several notable patient narratives.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c35566f1635eeaa794737d1de0e61a4
https://doi.org/10.1158/1078-0432.22457150
https://doi.org/10.1158/1078-0432.22457150
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b1720f9bb447ea9eda94114d5c9e67d
https://doi.org/10.1158/1078-0432.c.6523517
https://doi.org/10.1158/1078-0432.c.6523517
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Time to progression in relation to the immunohistological score in 16 patients with diverse cancers enrolled in the sacituzumab govitecan trial who provided archival tissue specimens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b466689fca03af0b9a50a231e8f610f
https://doi.org/10.1158/1078-0432.22457153.v1
https://doi.org/10.1158/1078-0432.22457153.v1
Autor:
David M. Goldenberg, Robert M. Sharkey, Steven A. Hamburger, William A. Wegener, Pius P. Maliakal, Serengulam V. Govindan, Sajeve S. Thomas, Linda T. Vahdat, Vincent J. Picozzi, Michael J. Guarino, Manish A. Shah, Allyson J. Ocean, Alexander N. Starodub
Trop-2 expression in archived tissue specimens from 6 patients enrolled in the clinical trial with sacituzumab govitecan.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0a91efb968a0bf05043b6d26295d33c
https://doi.org/10.1158/1078-0432.22457156
https://doi.org/10.1158/1078-0432.22457156
Autor:
Young Kwang Chae, Megan Othus, Sandip P. Patel, Raid Aljumaily, Khine Z. Win, Tanya Pejovic, Sajeve S. Thomas, William R. Robinson, Liam Il-Young Chung, Christine M. McLeod, Helen X. Chen, Elad Sharon, Howard Streicher, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock
Publikováno v:
Cancer Research. 83:CT163-CT163
Background: Dual checkpoint inhibition with Anti-PD-1 and anti-CTLA4 checkpoint inhibitors have shown to be efficacious in many malignancies, but its potential role in various rare solid cancers is yet to be established. Small cell ovarian carcinoma,
Autor:
Shailender Bhatia, John R. Hyngstrom, Alexandra Ikeguchi, Sajeve S. Thomas, Ann W. Silk, Dmitri Bobilev, Luping Zhao, James E. Wooldridge, Arthur M. Krieg, Diwakar Davar
Publikováno v:
Journal of Investigative Dermatology. 142:2837
Autor:
Juan C. Paramo, Sajeve S. Thomas, William Schmidt, Pallavi Kumar, Eddy C. Hsueh, Deepti Behl, Vinay Kumar Gupta, Prejesh Philips, Edward C. McCarron, Arvinda Padmanabhan, Adam C. Berger, Daniel Milton, Tawnya L. Bowles, Robert Weber, Jeffrey B Travers, Brendan D. Curti, Suthee Rapisuwon, Robert H.I. Andtbacka, Peter D. Beitsch, Mohammed M. Milhem, Edward A. Levine, John R. Hyngstrom, Suprith Badarinath, Anna Bar, John Keech, Marcus O. Butler, Omid Hamid, Brian R. Gastman, Andrew L. Pecora, Craig L. Slingluff, Takami Sato, J. Thaddeus Beck, Sekwon Jang, Catalin Mihalcioiu, John A. Glaspy, Karl D. Lewis, Shernan G. Holtan, Joël Claveau, Montaser Shaheen, Leonel Hernandez-Aya, Jose Lutzky, Brent A. Blumenstein, Joanna J Peterkin, Svetomir N. Markovic, Sujith Kalmadi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundMost patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plu
Autor:
Sajeve S. Thomas, Bin Zhang, Montaser Shaheen, David H. Lawson, April K.S. Salama, F. Stephen Hodi, Asim Amin, Stephen Francis, Troy H. Guthrie, Henry B. Koon, Steven J. O'Day
Publikováno v:
Journal for Immunotherapy of Cancer
Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant administration.